StocksMedium•29 September 2026•
1 min read
Kodiak Sciences Stock Surges 178% on Positive Phase III Eye Drug Data
Key Facts
1Kodiak Sciences stock surged 178% after the Phase III DAYBREAK trial met its primary endpoints.
2Data showed Zenkuda and tabirafusp-ted met key endpoints against Eylea for treating wet age-related macular degeneration.
Kodiak Sciences stock surged 178% after the Phase III DAYBREAK trial successfully met its primary endpoints. Zacks reported that the data demonstrated the success of Zenkuda and tabirafusp-ted against the comparator drug Eylea for treating wet age-related macular degeneration.
The massive rally in the share price on September 29, 2026, follows positive clinical data that provides a path for the company to file a Biologics License Application (BLA). These milestone results from the DAYBREAK study have significantly increased the company's valuation as it nears potential regulatory approval.